Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eyeing New Drugs For Glaucoma

This article was originally published in Start Up

Executive Summary

Demographic shifts leading to an increasing market, unmet medical need and potential interest from Big Pharma buyers are all compelling reasons for VCs to examine closely the opportunity in glaucoma. Add in the fact that because clinical trials are relatively straightforward and quick, it's possible to keep costs manageable, and one might expect venture capitalists to be rushing to form biotech start-ups in the glaucoma arena, especially since there's been no new mechanism of action in glaucoma in a long time. But the hurdle giving venture investors pause is the wholesale restructuring that will come to the glaucoma market next March, when a key patent for Xalatan expires.

You may also be interested in...



The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.

The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.

PanOptica Takes $30MM Series A Round, Licenses Ophthalmic Drug From Astellas

Seeking an easy-to-administer eye drop to treat AMD, the New Jersey startup drew on existing connections for a big first round.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092038

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel